ArticleJournal of translational internal medicine2021
The Lifetime Cost Estimation of Human Papillomavirus-related Diseases in China: A Modeling Study.
Article in Journal of translational internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- "A systematic literature review of the epidemiology, clinical, economic and humanistic burden in recurrent respiratory papillomatosis".Respiratory research · 2024Pooled it
- Economic evaluation of 22 HPV vaccination strategies to minimize the risk of penile, anal, and oropharyngeal cancers in Chinese males: A Markov model analysis.Human vaccines & immunotherapeutics · 2026Article
- Unveiling the microbial shift: the impact of group B Streptococcus on vaginal microbiota and inflammation in late pregnancy.BMC microbiology · 2025Article
- Optimizing strategy for cervical cancer prevention in china: a comprehensive modeling analysis.Cost effectiveness and resource allocation : C/E · 2025Article
- Human Papillomavirus Vaccination for Boys: Insights into Knowledge, Acceptance, and Willingness to Pay among Parents in Yogyakarta, Indonesia.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- The 2Human vaccines & immunotherapeutics · 2024Article
- Comprehensive succinylome analyses reveal that hyperthermia upregulates lysine succinylation of annexin A2 by downregulating sirtuin7 in human keratinocytes.Journal of translational internal medicine · 2024Article
- Cost-effectiveness of single-visit cervical cancer screening in KwaZulu-Natal, South Africa: a model-based analysis accounting for the HIV epidemic.Frontiers in oncology · 2024Article
- Estimation of economic burden throughout course of cervical squamous intraepithelial lesion and cervical cancer in China: A nationwide multicenter cross-sectional study.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Serum Spondin-2 expression, tumor invasion, and antitumor immune response in patients with cervical cancer.World journal of clinical cases · 2022Article
- Influence of group BWorld journal of clinical cases · 2022Article
- Ferroptosis: A mixed blessing for infectious diseases.Frontiers in pharmacology · 2022Review
- Factors Influencing Knowledge and Acceptance of Nonavalent Human Papillomavirus Vaccine Among University Population in Southern China: A Cross-Sectional Study.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the lifetime treatment costs of patients with human papillomavirus (HPV) infection-related diseases in China and to provide cost estimates for the economic evaluation of HPV intervention strategies.
methodsWe extracted real-world hospital data from 2012 to 2019 and screened for subjects who met the criteria of clinical diagnosis of HPV-related diseases to obtain country-specific inputs into a Markov decision model. The model simulated lifetime treatment costs for HPV from the perspective of a national payer. A 5% discount rate was applied. Costs were converted and inflated to 2020 US dollars (USD).
resultsUsing 2021 as the base year, the lifetime costs per patient for carcinoma in situ, local metastasis, and distant metastasis cervical cancer are $24,208 (95%CI: 18,793-30,897), $19,562 (95%CI: 14,456-25,567), and $17,599 (95%CI: 10,604-25,807), respectively. For carcinoma in situ, local metastasis, and distant metastasis vaginal cancer, the lifetime costs are $17,593 (95%CI: 14,962-23,596), $17,120 (95%CI: 13,215-22,417), and $22,411 (95%CI: 12,172-22,249), respectively. The base-case lifetime cost per patient for different stages of vulvar cancer/penile cancer/anal cancer/oral cancer/oropharyngeal cancer/laryngeal cancer falls within $17,120-$58,236.
conclusionsUsing real-world data, we calculated lifetime treatment costs of HPV-related cancer in China and found that the lifetime cost for patients exceeded $17,000 for various stages of disease. The national burden of HPV-related disease could be significantly reduced by eliminating HPV infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.